Merck's stock falls 1.91% to $79.96 despite broader market gain, investors await earnings release on July 29.
PorAinvest
sábado, 19 de julio de 2025, 11:46 am ET1 min de lectura
MRK--
Over the past month, Merck's stock had gained 2.81%, outperforming the Medical sector's loss of 1.59% but lagging the S&P 500's gain of 5.37% [1]. Investors are closely watching the company's upcoming earnings release, scheduled for July 29, 2025. Analysts anticipate an EPS of $2.01, a 11.84% decline from the same quarter last year. Revenue is expected to drop 2.48% to $15.71 billion [1].
The Zacks Consensus Estimates project earnings of $8.85 per share and revenue of $64.82 billion for the full year, indicating changes of +15.69% and +1.02% respectively, from the preceding year [1]. Analyst estimates have been revised downward, with Merck currently holding a Zacks Rank of #4 (Sell), indicating a sell signal [1].
From a valuation perspective, Merck trades at a Forward P/E ratio of 9.21, which is a discount compared to its industry average of 14.13 [1]. The PEG ratio, which also takes into account the company's expected earnings growth rate, stands at 0.85, lower than the industry average of 1.26 [1].
The Large Cap Pharmaceuticals industry, to which Merck belongs, has a Zacks Industry Rank of 74, placing it in the top 30% of all industries [1]. The Zacks Industry Rank evaluates industry groups based on the average Zacks Rank of individual stocks within them, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [1].
Investors should monitor Merck's upcoming earnings report and the subsequent changes in analyst estimates to gauge the company's performance and potential future stock price movements.
References:
[1] https://finance.yahoo.com/news/merck-mrk-falls-more-steeply-214504598.html
[2] https://www.nasdaq.com/articles/merck-mrk-falls-more-steeply-broader-market-what-investors-need-know
[3] https://www.nasdaq.com/articles/merck-mrk-falls-more-steeply-broader-market-what-investors-need-know-0
Merck's stock price has fallen 1.91% to $79.96, outpacing the broader market. The pharmaceutical company's upcoming earnings release on July 29, 2025, is expected to report a 11.84% decline in EPS to $2.01 and a 2.48% drop in revenue to $15.71 billion. Analysts have revised their estimates downward, with the Zacks Rank currently at #4 (Sell). Merck trades at a Forward P/E ratio of 9.21, a discount compared to its industry average.
Merck (MRK) closed the most recent trading day at $79.96, marking a 1.91% decrease from the previous session. This decline outpaced the broader market's performance, with the S&P 500 losing 0.01%, the Dow dropping 0.32%, and the tech-heavy Nasdaq gaining 0.05% [1].Over the past month, Merck's stock had gained 2.81%, outperforming the Medical sector's loss of 1.59% but lagging the S&P 500's gain of 5.37% [1]. Investors are closely watching the company's upcoming earnings release, scheduled for July 29, 2025. Analysts anticipate an EPS of $2.01, a 11.84% decline from the same quarter last year. Revenue is expected to drop 2.48% to $15.71 billion [1].
The Zacks Consensus Estimates project earnings of $8.85 per share and revenue of $64.82 billion for the full year, indicating changes of +15.69% and +1.02% respectively, from the preceding year [1]. Analyst estimates have been revised downward, with Merck currently holding a Zacks Rank of #4 (Sell), indicating a sell signal [1].
From a valuation perspective, Merck trades at a Forward P/E ratio of 9.21, which is a discount compared to its industry average of 14.13 [1]. The PEG ratio, which also takes into account the company's expected earnings growth rate, stands at 0.85, lower than the industry average of 1.26 [1].
The Large Cap Pharmaceuticals industry, to which Merck belongs, has a Zacks Industry Rank of 74, placing it in the top 30% of all industries [1]. The Zacks Industry Rank evaluates industry groups based on the average Zacks Rank of individual stocks within them, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [1].
Investors should monitor Merck's upcoming earnings report and the subsequent changes in analyst estimates to gauge the company's performance and potential future stock price movements.
References:
[1] https://finance.yahoo.com/news/merck-mrk-falls-more-steeply-214504598.html
[2] https://www.nasdaq.com/articles/merck-mrk-falls-more-steeply-broader-market-what-investors-need-know
[3] https://www.nasdaq.com/articles/merck-mrk-falls-more-steeply-broader-market-what-investors-need-know-0

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios